Duke Halts Third Trial; Coauthor Disputes Claim That Data Validation Was Blinded
Moffitt Ends Pilot Study Based On Duke Test, Says Action Unrelated
House DoD Report Provides $15 Million For Lung Cancer Screening
FDA Approves Votrient For Renal Cell Carcinoma
NCI Picks 11 Centers For Chemical Biology Consortium
IOM Report Says Smoking Bans Cut Heart Attack Risk
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs









